New York, NY -- (SBWIRE) -- 12/19/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Geron Corporation (NASDAQ:GERN), MFA Financial, Inc (NYSE:MFA), PDL BioPharma Inc (NASDAQ:PDLI), Harmony Gold Mining Co. (ADR) (NYSE:HMY)
Geron Corporation (NASDAQ:GERN) showed a volume of 3.28 million shares by the end of last trade whereas the average volume of the stock remained 8.15 million shares. The stock opened the session at $4.70 but then moved to $4.69. At that price, the stock showed a negative performance of -0.21%. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML).
Will GERN Get Buyers Even After The Recent Rally? Find Out Here
MFA Financial, Inc (NYSE:MFA) opened the session at 7.18 and closed the session at $7.27. The stock showed a positive performance of 1.25% in previous trading session. Traded with volume of 3.27 million shares in the prior session and the average volume of the stock remained 3.53 million shares. MFA Financial, Inc., is engaged in the business of investing, on a leveraged basis, in residential Agency mortgage-backed securities (MBS) and Non-Agency MBS. Its business objective is to generate net income for distribution to its stockholders resulting from the difference between the interest and other income it earn on its investments and the interest expense it pays on the borrowings, which it uses to finance its leveraged investments and its operating costs. Its operating policies require that at least 50% of its investment portfolio consist of ARM-MBS,
For How Long MFA will fight for Profitability? Read This Trend Analysis report
PDL BioPharma Inc (NASDAQ:PDLI) opened the session at $8.12 and closed the session at $8.38. The stock showed a positive performance of 3.84% in previous trading session. Traded with volume of 3.26 million shares in the prior session and the average volume of the stock remained 3.13 million shares. The beta of the stock remained 0.62. PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014.
Why Should Investors Buy PDLI After The Recent Gain? Just Go Here and Find Out
Harmony Gold Mining Co. (ADR) (NYSE:HMY) the stock decreased -2.02% and finished the session at $2.42. Traded with volume of 3.24 million shares in the prior session and the average volume of the stock remained 2.45 million shares. The beta of the stock remained 0.12. Harmony Gold Mining Company Limited (Harmony) is engaged in conducting underground and surface gold mining and related activities, including exploration, processing and smelting. During the fiscal year ended June 30, 2012 (fiscal 2012), its mining operations reported total proven and probable reserves of 52.9 million ounces (including gold equivalent ounces), primarily from South African sources. During fiscal 2012, we processed 20.7 million tons of ore. During fiscal 2012, approximately 84% of its gold came from the Company’s South African underground mines,
Will HMY Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)